Back
 JBM  Vol.7 No.11 , November 2019
Monitoring the Treatment of Hepatitis C Viral Infection by Molecular Techniques
Abstract: The prevalence of Hepatitis C viral infection in Egypt is the highest rate in the world. It is a major public health problem in Egypt. The objective of this study was to detect the clearance of HCV-RNA in Egyptian patients who were recommended for combination therapy of pyglated interferon α 2a and ribavirin (PEG-interferon/Ribavirin). Ninety-five positive HCV-IgG cases were tested for HCV-RNA at baseline and at weeks 4, 12, 24, 48 and 72 of treatment with PEG-interferon α 2a/Ribavirin. The correlations between the viral parameters during and after treatment were evaluated. Patients recommended receiving PEG-interferon 2a/ribavirin combination therapy showed high response rate determined as 71.9% achieved Sustained Virological Response (SVR) from total patients, and 71.4% from patients who received 48 weeks therapy. In general, the employment of TMA provided us the accuracy of results with confidence in our work. There was a significant relation (p < 0.001) between results of Transcription mediated amplification (TMA) and response to therapy that indicate to positive correlation. The development of sensitive accurate assays for HCV-RNA detection and quantification is necessary to improve not only the assessment of the response to antiviral therapy but also our understanding of the mechanism underlying antiviral resistance.
Cite this paper: Nabil, M. , Al-Dahr, M. , Haridi, A. , Mohamed, W. , Abdalhabib, E. and Mazahari, B. (2019) Monitoring the Treatment of Hepatitis C Viral Infection by Molecular Techniques. Journal of Biosciences and Medicines, 7, 91-100. doi: 10.4236/jbm.2019.711008.
References

[1]   Morozov, V. and Lagaye, S. (2018) Hepatitis C virus: Morphogenesis, Infection and Therapy. World Journal of Hepatology, 10, 186-212.
https://doi.org/10.4254/wjh.v10.i2.186

[2]   Kim, C.W. and Chang, K.M. (2013) Hepatitis C Virus: Virology and Life Cycle. Clinical and Molecular Hepatology, 19, 17-25.
https://doi.org/10.3350/cmh.2013.19.1.17

[3]   Elgharably, A., Gomaa, A., Norsworthy, P. and Taylor-Robinson, S. (2017) Hepatitis C in Egypt: Past, Present, and Future. International Journal of General Medicine, 10, 1-6.
https://doi.org/10.2147/IJGM.S119301

[4]   Lagaye, S., Shen, H., Rousseau, G. and Pol, S. (2013) Major Models of Hepatitis C Virus Infection. Future Virology, 8, 493-506.
https://doi.org/10.2217/fvl.13.29

[5]   Scott, J.D. and Gretch, D.R. (2007) Molecular Diagonostics of Hepatitis C Virus Infection. JAMA, 297, 724-732.
https://doi.org/10.1001/jama.297.7.724

[6]   American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (2015) Recommendations for Testing, Managing, and Treating Hepatitis C.
http://hcvguidelines.org/full-report-view

[7]   WHO (2014) Guidelines for Screening, Care and Treatment of Persons with Hepatitis C Infection. Publications on Viral Hepatitis.
http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en

[8]   Sharma, S.D. (2010) Hepatitis C Virus: Molecular Biology & Current Therapeutic Options. Indian Journal of Medical Research, 131, 17-34.

[9]   Seeff, L.B. (2002) Natural History of Chronic Hepatitis C. Journal of Hepatology, 36, S35-S46.
https://doi.org/10.1053/jhep.2002.36806

[10]   Wong, T. and Lee, S.S. (2006) Hepatitis C: A Review for Primary Care Physicians. Canadian Medical Association Journal, 174, 649-659.
https://doi.org/10.1503/cmaj.1030034

[11]   Ponziani, F.R., Gasbarrini, A., Pompili, M., Burra, P. and Fagiuoli, S. (2011) Management of Hepatitis C Virus Infection Recurrence after Liver Transplantation: An Overview. Transplantation Proceedings, 43, 291-295.
https://doi.org/10.1016/j.transproceed.2010.09.102

[12]   Day, C.L., Lauer, G.M., Robbins, G.K., McGovern, B., Wurcel, A.G., Gandhi, R.T., Chung, R.T. and Walker, B.D. (2002) Broad Specificity of Virus-Specific CD4+ T-Helper-Cell Responses in Resolved Hepatitis C Virus Infection. Journal of Virology, 76, 12584-12595.
https://doi.org/10.1128/JVI.76.24.12584-12595.2002

[13]   Wanis, H., Hussein, A., El Shibiny, A., et al. (2014) HCV Treatment in Egypt: Why Cost Remains a Challenge Egyptian Initiative for Personal Rights. 6-18.
http://www.eipr.org/sites/default/fles/pressreleases/pdf/hcv_treatment_in_egypt.pdf

[14]   Lauer, G.M., Barnes, E., Lucas, M., Timm, J., Ouchi, K., Kim, A.Y., Day, C.L., Robbins, G.K., Casson, D.R., Reiser, M., Dusheiko, G., Allen, T.M., Chung, R.T., Walker, B.D. and Klenerman, P. (2004) High Resolution Analysis of Cellular Immune Responses in Resolved and Persistent Hepatitis C Virus Infection. Journal of Gastroenterology, 127, 924-936.
https://doi.org/10.1053/j.gastro.2004.06.015

[15]   Derbala, M.F., Al-Kaabi, S.R., El-Dweik, N.Z., Pasic, F., Butt, M.T., Yakoob, R., Al-Marri, A., Amer, A.M., Morad, N. and Bener, A. (2006) Treatment of Hepatitis C Virus Genotype 4 with Peginterferon Alfa-2a: Impact of Bilharziasis and Fibrosis Stage. World Journal of Gastroenterology, 12, 5692-5698.
https://doi.org/10.3748/wjg.v12.i35.5692

[16]   Al Ashgar, H., Khan, M.Q., Helmy, A., Al Swat, K., Al Sherhri, A., Al Kalbani, A., Preedikayel, M., Al Kahtani, K., Al Quaiz, M., Rezeig, M., Kagevi, I. and Al Fadda, M. (2008) Sustained Virologic Response to Peginterferon Alpha-2a and Ribavirin in 335 Patients with Chronic Hepatitis C: A Tertiary Care Center Experience. Saudi Journal of Gastroenterology, 14, 58-65.
https://doi.org/10.4103/1319-3767.39619

[17]   Chevaliz, S. and Pawlotsky, J.M. (2007) Hepatitis C Virus Virological Tests and Clinical Diagonosis of HCV-Related Liver Disease. International Journal of Medical Sciences, 3, 35-40.
https://doi.org/10.7150/ijms.3.35

[18]   Pantua, H., Diao, J., Ultsch, M., Hazen, M., Mathieu, M., McCutcheon, K., Takeda, K., Date, S., Cheung, T.K., Phung, Q., Hass, P., Arnott, D., Hongo, J.A., Matthews, D.J., Brown, A., Patel, A.H., Kelley, R.F., Eigenbrot, C. and Kapadia, S.B. (2013) Glycan Shifting on Hepatitis C Virus (HCV) E2 Glycoprotein Is a Mechanism for Escape from Broadly Neutralizing Antibodies. Journal of Molecular Biology, 425, 1899-1914.
https://doi.org/10.1016/j.jmb.2013.02.025

[19]   Alberti, A. (2009) What Are the Comorbidities Influencing the Management of Patients and the Response to Therapy in Chronic Hepatitis C? Liver International, 29, 15-18.
https://doi.org/10.1111/j.1478-3231.2008.01945.x

[20]   Martin-Carbonero, L., Nuneza, M., Marino, A., Alcocer, F., Bonet, L., Javier Garcia-Samaniego, J., Pilar Lopez-Serrano, P., Cordero, M., Joseba Portu, J. and Sorianoa, V. ( 2008) Undetectable Hepatitis C Virus RNA at Week 4 as Predictor of Sustained Virological Response in HIV Patients with Chronic Hepatitis C. Aids, 22, 15-21.
https://doi.org/10.1097/QAD.0b013e3282f1da99

[21]   Abdel-Razik, M.B. (2007) Evaluation of Various Modalities for Treatment of Chronic Hepatitis C. PhD Thesis, Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Vol. 96, 12766-12771.

[22]   Lindsay, K.L. (2002) Introduction to Therapy of Hepatitis C. Journal of Hepatology, 36, S114-S120.
https://doi.org/10.1053/jhep.2002.36226

[23]   Zekri, A.R., El-Din, H.M., Bahnassy, A.A., Khaled, M.M., Omar, A., Fouad, I., El-Hefnewi, M., Thakeb, F. and El-Awady, M. (2007) Genetic Distance and Heterogenecity between Quasispecies Is a Critical Predictor to IFN Response in Egyptian Patients with HCV Genotype-4. Virology Journal, 14, 16.
https://doi.org/10.1186/1743-422X-4-16

 
 
Top